Seamless Drug Development

By Ewoud-Jan Van Hoogdalem, Andre Van Vliet, and Lynn Webster, PRA Health Sciences

The failure rate in clinical drug development is high for several reasons. One is the infinite complexity of the human body with its myriad of chemical and biological pathways potentially involved in disease. Furthermore, it is challenging to design an effective remedy for either small or large molecules. Lastly, in many cases failure arises not from the science, but from circumstances such as limited resources, budgets, experience, expertise or a combination of these. As your partner, PRA is ready to meet these challenges. We complement your internal organization by offering experience and expertise in all disciplines of clinical development in numerous therapeutic areas, including treatments for rare diseases.